AstraZeneca and Daiichi Sankyo’s breast cancer therapeutic Enhertu received supplemental approval from the U.S. Food and Drug Administration. Enhertu was approved for treating adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy.
Cosette Pharmaceuticals Inc., a New Jersey-based pharmaceutical company, announced the launch of Prochlorperazine Edisylate injection, 10 mg/2ml (5mg/ml).
As part of a restructuring of the company’s research and development areas, Tokyo-based Daiichi Sankyo announced the closing of the Plexxikon R&D subsidiary in South San Francisco.
Companies presented very promising data for treating lung cancer at European Society of Medical Oncology (ESMO) Congress 2021.